Dr. Chapin on Impact of Active Surveillance in Field of Prostate Cancer

Video

In Partnership With:

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

There has been a large, national increase in the number of patients going onto active surveillance programs, Chapin explains. Compared with the smaller proportion seen previously, researchers now are seeing that up to 40% of men who are diagnosed with low-risk tumors are going onto an active surveillance program.

Additionally, he says, the community is recognizing that not all prostate cancers are the same. Some prostate cancers are indolent and are unlikely to cause significant problems. Patients are becoming more aware of that; therefore, they are seeking out other options and not just choosing to go with active treatment.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD